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Biopsy in Renal Cell Carcinoma 
Surveillance Epidemiology and End Results (SEER) estimates that 58,240 people will be 
diagnosed with cancer of the kidney and renal pelvis, while 13,040 will die in 2010
1
. Renal cell 
cancer accounts for about two percent of all adult cancers
2
. More than 80% of cancers of the 
kidney arise in the renal parenchyma, while the rest arise in the pelvis
3
. Historically, renal cell 
carcinoma (RCC) has been treated with nephrectomy, often with no tissue diagnosis, because of 
the adverse effects and possibility of false negatives associated with renal mass biopsy. With the 
advancement of imaging modalities in the last decades, smaller tumors are now being discovered 
that pose therapeutic dilemmas that did not exist in the past. Growing numbers of studies are 
showing a substantial proportion of these masses is benign on nephrectomy pathology leading 
urologists to question the current paradigm and reconsider biopsy
4, 5
. Due to improved sampling 
techniques and advances in immunohistochemistry, recent studies have reported higher levels of 
sensitivity and specificity for biopsy than were previously reported in the literature
6-8
. If biopsy 
could be proven to be dependable, options such as active surveillance and ablative therapies 
could provide physicians and patients with better choices if patients are not good surgical 
candidates.  
Etiology  
Though the exact mechanisms of carcinogenesis remain uncertain, tobacco and obesity 
are the two biggest risk factors for renal cell carcinoma (RCC), associated with 20% and 30% of 
cases, respectively
910
. Another important risk factor is hypertension, which has been proven to 
act via an independent mechanism from obesity
9
. While initial studies suggested a link between 
analgesics and RCC, recent studies with acetaminophen, aspirin, and NSAIDs showed no 
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significant relationship to cancer. This may be due to the fact that initial studies considered 
phenacetin, which has now been off the market for over 25 years
9
. Studies have failed to show a 
significant association between diet and RCC
9
. 
Tumor Characteristics 
In 2002, the International Union Against Cancer (UICC) updated the TNM staging 
system for renal cell carcinoma by further classifying the T1 group into T1a and T1b; T1a refers 
to tumors within the kidney that are less than or equal to four centimeters, while T1b refers to 
tumors within the kidney that are between four and seven centimeters
11
. Stage II cancer is larger 
than 7 centimeters but is still limited to the kidney. Stage III refers to tumors that have spread to 
one lymph node or into the fatty tissue or veins around the kidney, but not to any distant organs. 
Lastly, Stage IV cancer involves spread to more than one lymph node, a lymph node not near the 
kidney, or to distant sites
12
. With regards to RCC grading, Fuhrman et al. presented a system 
based on 100 patients after nephrectomy in which four nuclear grades were defined based on 
size, irregularity and nucleolar prominence. Though many alternate grading schemes have been 
presented, the Fuhrman grading system remains the most widely used system in the United 
States
12
.  
Changes in Epidemiology 
Incidence rates of RCC have increased steadily over the past two decades in the United 
States and the trend is accompanied by an increase in early stage cancer 
13
. Historically, renal 
cancer was diagnosed based on a triad of symptoms including flank pain, a flank mass, and 
hematuria. More recently, due to the ubiquity of modern imaging, a large proportion of renal 
masses are found incidentally before any symptoms are present. A 1998 paper examined cases of 
 3 
 
RCC at Yale New Haven Hospital from 1989 and 1993 and found that more than 60% were 
discovered incidentally on imaging and showed this to be an increasing trend compared to 
previous decades
2
. Of the 135 pathology specimens collected from the lab, 131 had complete 
medical records accessible. The authors referred to masses as incidental if they lacked signs or 
symptoms of RCC, such as flank mass, flank pain, or hematuria, or if the physician had no 
suspicion of RCC as noted in the medical record. Findings such as these have been attributed to 
increasing detection of asymptomatic tumors by imaging procedures such as ultrasound, 
computed tomography and magnetic resonance imaging.  Unpublished data from the Health Care 
Financing Administration, which reported a 73% rise in abdominal/pelvic CT scans or MRIs to 
Medicare beneficiaries, supports this hypothesis
3
. The increased detection is coupled with a 
decrease in the average size of masses at diagnosis due to the advancing precision of imaging 
modalities; a recent study reported a decrease in mean tumor size from 4.1 to 3.6 cm between 
1993 and 2004
14
.  
 Based on the idea that prompt removal of tumors leads to better survival outcomes, an 
increase in the rate of nephrectomy has mirrored the increase in incidence of renal masses
15
.  A 
paper by Hollingsworth et al. collected information on 40,813 cases of RCC from nine SEER 
areas and found that from 1983 to 2002, the overall incidence of RCC increased from 7.1 to 10.8 
cases per 100,000 people, an increase of 52%. The largest increase was observed in tumors 
between two and four centimeters. For each tumor size category, there was a similar increase in 
the rate of renal surgery in the same time period. These data showed a substantially higher 
increase in incidence than a similar paper using SEER data by Chow et al. which showed 
between a 2.3% and 4.3% increase in renal cell cancer incidence between 1975-1977 and 1993-
1995
3
. Despite increased rates of surgical treatment, the study found that RCC-specific mortality 
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rates rose from 1.2 to 3.2 deaths per 100,000 people, with an increase seen in all tumor size 
groups. Although five-year survival for RCC has improved in that time period, the overall 
mortality has increased, which the authors attribute to lead and length time bias. Because smaller 
tumors are being detected, the five-year survival percentages are increasing, but overall survival 
is not. The authors argue that despite earlier detection of masses and increased rates of surgery, 
population data do not show a decrease in mortality, which argues for “a reassessment of the 
current treatment paradigm.” As the authors admit, the study does have limitations. Among 
them, SEER does not collect patient comorbidity data and thus it is impossible to know the 
causes of mortality in all patients. Additionally, over 15% of patients were missing tumor size 
information and were excluded from the study
16
.  
Imaging 
Because of the increased accessibility and quality of imaging, renal masses are now 
routinely found on CT scans and MRIs. When examining renal masses on imaging, radiologists 
assess calcification, pattern (homogenous vs. heterogenous), attenuation, septations, wall 
characteristics, contrast enhancement, and enhancement patterns
17
.  While many findings, such 
as contrast enhancement and noncalcification, are more common in carcinomatous lesions, 
benign lesions have also been shown to have these features
17
. Thus, many authors have 
concluded that despite substantial advancements in technology and resolution, imaging alone 
cannot distinguish between malignant and benign masses with certainty 
18
.  A study from 2004 
examined 162 solid renal masses that were initially evaluated using imaging, and found that 145 
were renal cell carcinomas and 17 were benign. Of the 17 benign cases, 16 of the patients 
underwent some sort of surgical procedure
18
. Despite recent efforts to increase the accuracy of 
imaging, traditional findings such as a homogenous hypervascular appearance or a spoke-wheel 
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on angiography have been shown to be neither sensitive nor specific
19
. Although recent advances 
in imaging allow accurate differentiation between cystic and solid lesions, differentiating benign 
and malignant renal masses remains largely unreliable
20, 21
. 
 Imaging can be diagnostic, however, in one specific type of renal mass: 
angiomyolipomas, also known as renal hamartomas. According to studies by Bosniak, 
attenuation of fat on CT scans in angiomyolipomas can be diagnostic in more than 90% of these 
masses
22
 
23
. However, when angiomyolipomas have no fat present on imaging, they are 
indistinguishable from renal cell carcinoma and merit further investigation
24
.  
Treatment 
Despite substantial advances in oncologic treatment, renal cancer still remains resistant to 
standard chemotherapeutic agents. However, low stage RCC can be successfully treated with 
extirpative surgery, with better prognosis for those with lower stage disease
25
. Historically, 
radical nephrectomy, with wide excision of the kidney outside of Gerota’s fascia to include the 
adrenal gland and perirenal fat, was preferred because of concern that extrarenal involvement 
lead to surgical failure
26
.  However, nephron-sparing surgery, initially performed in those with a 
solitary kidney or pre-existing renal insufficiency with the hopes of preserving renal function, 
has become increasingly popular in recent decades. 
 In a 2000 paper, Lau et al. conducted a retrospective analysis of radical nephrectomy 
versus nephron-sparing surgery. The patients were matched on age, sex, tumor size, pathologic 
tumor stage and grade, and year in which the surgery was performed. The study showed that over 
a 15 year follow-up, 77% of those undergoing radical nephrectomy were alive with no evidence 
of disease compared with 79% of nephron-sparing surgery patients. At ten year follow-up, there 
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were similar rates of contralateral recurrence and metastasis. The cumulative incidence of 
chronic renal insufficiency (defined as greater than 2.0 mg/dL at least 30 days after surgery) was 
22.4% and 11.6% in the radical nephrectomy group and nephron-sparing surgery group, 
respectively. The authors suggest that nephron-sparing surgery is as effective as radical 
nephrectomy from an oncologic standpoint and may potentially have better outcomes with 
respect to complications. Compared to earlier studies in which nephron-sparing surgery was only 
done in those with solitary kidneys or pre-existing renal insufficiency, the study enrolled patients 
with single unilateral RCC and a normal contralateral kidney, which strengthens generalizability. 
These findings coincided with those from a multi-center Austrian study as well as a single 
institution German study showing comparable cancer-free survival in nephron-sparing surgery 
versus radical nephrectomy
27,28
. 
 However, due to its non-randomized and retrospective design, the conclusions from this 
study are limited. Despite matching on tumor size, the average size in the radical nephrectomy 
group was 3.7 cm compared with 3.3 cm in the nephron-sparing surgery group, with the 
difference being statistically significant. It is likely that the smaller size of tumors in the 
nephron-sparing surgery group could have led to improved outcomes both in terms of oncologic 
outcome and renal function. It is also impossible to match and adjust for all the potential factors 
that could affect survival and renal function retrospectively. A prospective randomized control 
trial addressed this issue in a study that recruited patients with small (≤5 cm) solitary, T1-T2 N0 
M0 masses and a normal contralateral kidney. The authors randomized patients to nephron 
sparing surgery or radical nephrectomy and analyzed overall survival, with disease-specific 
survival, progression, and surgical side effects as secondary end-points. The two groups were 
similar with regard to age, tumor size, tumor stage, tumor grade, and WHO performance status.  
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The intention-to-treat analysis showed a 10-year overall survival rate of 75.7% for NSS and 
81.1% for RN, with an estimated hazard ratio of 1.50 (95% CI 1.03-2.16). However, this number 
became insignificant when the analysis was limited to those with actual renal cell carcinoma 
rather than surgery performed for benign masses. The hazard ratio of death from renal cancer 
was not significantly higher in the NSS group, nor was progression of cancer. A major weakness 
of the study was that the authors reported recruiting only 541 patients due to poor accrual despite 
calculating a necessary sample size of 1300 patients to detect a proposed 3% difference in 5-year 
survival.  Additionally, the authors reported that 5.9% of the patients randomized to radical 
nephrectomy underwent nephron sparing surgery and 14.6% of patients randomized to nephron 
sparing surgery underwent radical nephrectomy
29
. The finding that overall survival is slightly 
better in RN than NSS is in contrast with many previously published studies on this topic. 
However, those studies are limited by their retrospective design, heterogeneous stage of tumors 
between groups, and lack of renal function outcomes. As far as we know, this is the only 
randomized trial to date on this subject and more studies like this need to be done in order to 
definitively answer this question.  
In 2007, Novick and Derweesh outlined absolute, relative, and elective indications for 
nephron-sparing surgery compared to radical nephrectomy. Absolute indications apply to 
situations in which nephrectomy would result in an immediate need for dialysis. Such situations 
include patients with a solitary kidney, bilateral renal cell carcinoma, or patients in whom the 
contralateral kidney cannot sustain normal kidney function. Relative contraindications apply to 
situations in which the long-term viability of the remaining kidney is in doubt, such as stone 
disease, chronic pyelonephritis, renal artery stenosis, or systemic diseases such as diabetes. 
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Elective indications are for those patients with unilateral renal cell carcinoma less than 4 cm and 
a normal contralateral kidney
26
.  
Benign Findings on Nephrectomy 
For tumors smaller than 4 cm, the gold standard for treatment is radical or nephron 
sparing surgery
30
. However, a paper from 1987 showed that roughly 15% of renal masses 
detected on CT scan were benign
31
. More recent papers have shown even higher rates of benign 
findings on nephrectomy pathology. In a paper published in 2003, Lane and Gill retrospectively 
examined patients who underwent laparoscopic partial nephrectomies at the Cleveland Clinic 
and found 56 patients with at least five years of follow-up. Though the purpose of the study was 
to report oncologic outcomes after partial nephrectomy, the data showed a benign diagnosis on 
final pathology in 19 of the 56 patients (38%)
32
. These numbers may not provide an accurate 
representation of the proportion of benign masses because some of the masses were 
symptomatic; in a population of asymptomatic incidental renal masses, it is possible that the 
proportion of benign masses would be even higher. A similar paper in 2006 found that 38 of 123 
(31%) masses removed by laparoscopic partial nephrectomy were found to be benign on final 
pathology. The average size of the masses in the study was 2.6 cm, which is promising for 
generalizability to small renal masses, which are generally considered to be less than 4 cm. The 
indications for nephrectomy, however, were difficult to ascertain as the authors only reported 
performing surgery for “enhancing renal masses33.” In 2007, Gill et al. reported their findings of 
1800 laparoscopic and open partial nephrectomies, showing that 21.4% of nephrectomy 
specimens showed benign histology
5
.  
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  The proportion of nephrectomies for benign masses is even more disconcerting when 
stratified by size, as shown in a case series by Frank et al. that examined 2770 nephrectomies due 
to solid renal masses and found that those less than 3 cm were 25% benign, those less than 2 cm 
were 30% benign and those less than 1 cm were 44% benign
34
.  With the average age of RCC 
being 65 years old, many patients undergoing procedures are at higher risk for post-operative 
complications or mortality due to various comorbidities
30
. Because of this increased risk, active 
surveillance and modern ablative therapies are likely a better option in this population. Biopsy, if 
proven to be accurate and dependable, could assist the physician and the patient in making a 
more informed decision. Even young patients may have chronic renal insufficiency, solitary 
kidneys, or other medical conditions that seriously complicate surgery; thus, watchful waiting 
would be a welcome option to many patients if it could be proven as a safe alternative
35
.   
The resurgence of biopsy 
Benign findings on nephrectomy and the known indolence of small malignancies coupled 
with the emergence of newer treatments such as radio-frequency ablation and cryoablation, 
which require pre-procedure biopsy, have caused physicians to reconsider the role of renal mass 
biopsy
19
. Supporters of biopsy claim that it is safe, that the majority of biopsied lesions are 
benign, and that biopsy can decrease unnecessary surgery
34
. Opponents argue that biopsy carries 
too high a risk of false negatives
36
, can lead to biopsy track seeding with cancer cells, and leads 
to complications
37
.  
While bleeding when the renal capsule is punctured is to be expected with biopsy, one 
case series showed that renal hemorrhage resulting in hospitalization or blood transfusion 
occurred in 1% to 2% of biopsies
38
. A more recent series in which a CT was taken immediately 
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after biopsy to check for complications, the authors reported no patients in whom a hematoma 
was found or any patients requiring intervention related to biopsy complications
7
. In a meta-
analysis by Lane et al., the authors observed complications in renal mass biopsies in seven case 
series done after 2001. Out of a total of 362 biopsies, one series in the review showed one major 
complication from biopsy while the remaining six showed zero major complications. There were 
17 minor complications reported in the review
19
. An important consideration is that these are 
case series reported from academic centers, and that their characteristics may not be applicable to 
all types of hospitals or urology practices.  The authors did not report skills levels of surgeons or 
the volume of cases that these centers are exposed to. Additionally, the papers did not adjust for 
baseline status of the patients and thus conclusions are limited. 
A case report of biopsy needle track seeding with malignant cells from a study in 1991 
raised alarms about the risk of percutaneous biopsy
39
. Recently, however, reports of tumor 
seeding have been exceedingly rare, in part because of the use of the coaxial system. This 
approach uses a larger gauge introducer which then remains in place while a smaller needle can 
make multiple passes to obtain tissue
20
. This approach has been reported to reduce the chance of 
tumor seeding because it limits the number of times the renal capsule is penetrated
40
. Numerous 
reports with follow-up periods ranging from one to five years have shown no evidence of needle 
track seeding
38, 40-42
. The main argument against these findings is that the follow-up period may 
not be long enough to detect possible tumor seeding.  
Not only have the rates of complications and tumor seeding been shown to be lower than 
suspected, but the historically poor numbers for biopsy sensitivity and specificity may be more 
complicated than previously considered as well. Historically, studies have regarded inconclusive 
or failed biopsies as false negatives when calculating sensitivity and specificity for renal mass 
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biopsy. For example, in an American Urology Association Update Series from 2000, the authors 
report sensitivity for core biopsy of renal masses as low as 70% and state that “false negatives 
are most often due to insufficient specimens which are often bloody aspirates.” Based on these 
reports, they conclude that biopsy is not indicated for a solitary renal lesion that looks like RCC 
on imaging
43
. However, taking these biopsies out of the denominator can portray a drastically 
different situation depending on the frequency of biopsy failure. In more recent studies, where 
inconclusive biopsies, i.e. those showing normal renal parenchyma, necrotic tissue, or 
hemorrhage are excluded from the analysis, the accuracy of biopsy in deciphering benign versus 
malignant masses has been reported between 89% and 98%
6, 7, 44
. Because false negatives based 
on an adequate sample have been shown to be less common
38
 
45, 46
, it is possible that the rising 
sensitivity values seen in recent studies are attributed not to improvements in techniques, but to 
improvements in denominators. 
Regardless of the classification of non-diagnostic biopsies, multiple studies have shown 
that the use of biopsy decreases the number of surgeries performed for renal masses, with Wood 
et al. reporting a 41% decrease in the number of surgeries and Somani et al. reporting 24% of 
patients avoiding surgery
38, 47
. In light of new information and changing opinions, this paper 
aims to examine the literature for the sensitivity and specificity of renal mass biopsy in those 
with incidentally detected small renal masses and to report the frequency of adverse events 
including bleeding episodes and needle track seeding.  
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Methods 
This systematic review included published studies describing different measures of performance 
for renal mass biopsy in imaging-detected small renal masses. Biopsy of renal masses is 
currently not routine practice and thus the studies were limited to academic medical centers 
participating in research. Because of recent advances in immunohistochemistry and pathology 
techniques, we sought to perform a review of recent articles and chose 2005 as a cutoff. In 
March 2011, we identified prospective or retrospective cohort studies and case series by 
searching the MEDLINE and EMBASE databases from January 1, 2005 to March 1, 2011. We 
also hand searched reference lists. A research librarian at the University of North Carolina 
Health Sciences Library assisted in creation of the search strategy. 
We searched the following terms in MEDLINE: 
("Kidney Neoplasms"[Majr] AND "Biopsy"[Mesh] AND ("Predictive Value of Tests"[mh] OR 
"Sensitivity and Specificity"[mh] OR "Reproducibility of Results"[mh] OR "Retrospective 
Studies"[mh] OR "Risk Assessment"[mh] OR "Prognosis"[mh] OR "Incidental Findings"[mh] 
OR "diagnosis"[Subheading] OR "classification"[Subheading] OR "pathology"[Subheading]))  
(English[lang] AND "adult"[MeSH Terms].  
[majr] = Major MeSH term 
[mh] = MeSH term 
[sh] = Subheading 
 
We searched the following terms in EMBASE: 
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“kidney tumor'/exp/mj AND biopsy'/exp/mj AND ('predictive value of tests' OR 'sensitivity and 
specificity' OR 'reproducibility of results' OR 'retrospective studies' OR 'risk assessment' OR 
'prognosis' OR 'incidental findings' OR 'diagnosis' OR 'classification' OR 'pathology') 
Limits: Humans; English” 
Two readers independently first reviewed all titles identified by both searches excluding 
those about non-renal malignancies, editorial or “letter” articles, studies not discussing biopsy, 
and individual patient case reports. The readers then read the remaining abstracts excluding those 
in which renal masses over 5 cm were reported, articles reported ex-vivo biopsies, articles 
reported laparoscopic biopsies, and articles that reported biopsy before radiofrequency ablation. 
All remaining articles were fully reviewed. 
In the full review, we sought prospective or retrospective cohort studies and case series in 
which patients underwent renal mass biopsy for a renal mass detected on imaging and suspected 
to be renal carcinoma. Because the average age at diagnosis of renal cell carcinoma is 65 years 
old, we considered patients over age 40 in order to include as many patients as possible. It was 
important to have an age minimum in order to prevent pediatric renal cancers from being 
included in the review, because their pathology and epidemiology are quite different from adult 
renal cancers. We did not discriminate based on biopsy technique, i.e. FNA versus core biopsy, 
or on needle size. . We did not discriminate based on nephrectomy technique, i.e. open radical 
nephrectomy, laparoscopic radical nephrectomy, open partial nephrectomy, or laparoscopic 
partial nephrectomy. Our primary outcomes were sensitivity and specificity of biopsy findings 
compared to ex vivo pathology findings after nephrectomy, rate of adverse events, and findings 
of needle track seeding. Secondary outcomes were sensitivity and specificity for RCC subtype 
and Fuhrman grade, and percentage of diagnostic or “conclusive” biopsies. 
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Population Adults over age 40 with incidentally detected renal mass found on 
imaging 
Intervention Image-guided biopsy 
Comparison If nephrectomy specimen available, compare biopsy findings to 
nephrectomy pathology 
 
If no nephrectomy, consider 2 year symptom-free surveillance of a 
benign biopsy correct  
Outcome Benign versus malignant biopsy result 
Time At least a two-year follow-up of cases under surveillance 
Setting Academic medical centers 
Study Type Randomized control trials, cohort studies, case series 
Table 1. USPSTF criteria for cohort studies. 
Quality Assessment Tool 
The United States Preventive Services Taskforce provides the following criteria for randomized 
control trials and cohort studies:  
 Initial assembly of comparable groups:  
o For RCTs: adequate randomization, including first concealment and whether 
potential confounders were distributed equally among groups. 
o For cohort studies: consideration of potential confounders with either restriction 
or measurement for adjustment in the analysis; consideration of inception cohorts. 
 Maintenance of comparable groups (includes attrition, cross-overs, adherence, 
contamination). 
 Important differential loss to follow-up or overall high loss to follow-up. 
 Measurements: equal, reliable, and valid (includes masking of outcome assessment). 
 Clear definition of interventions. 
 All important outcomes considered. 
 Analysis: adjustment for potential confounders for cohort studies, or intention to treat 
analysis for RCTs. 
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Based on these criteria, the USPSTF offers the following three categories: 
Good: Meets all criteria: Comparable groups are assembled initially and maintained throughout 
the study (follow-up at least 80 percent); reliable and valid measurement instruments are used 
and applied equally to the groups; interventions are spelled out clearly; all important outcomes 
are considered; and appropriate attention to confounders in analysis. In addition, for RCTs, 
intention to treat analysis is used. 
Fair: Studies will be graded "fair" if any or all of the following problems occur, without the fatal 
flaws noted in the "poor" category below: Generally comparable groups are assembled initially 
but some question remains whether some (although not major) differences occurred with follow-
up; measurement instruments are acceptable (although not the best) and generally applied 
equally; some but not all important outcomes are considered; and some but not all potential 
confounders are accounted for. Intention to treat analysis is done for RCTs. 
Poor: Studies will be graded "poor" if any of the following fatal flaws exists: Groups assembled 
initially are not close to being comparable or maintained throughout the study; unreliable or 
invalid measurement instruments are used or not applied at all equally among groups (including 
not masking outcome assessment); and key confounders are given little or no attention. For 
RCTs, intention to treat analysis is lacking. 
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Figure 1. Search strategy and outcomes. 
 
  
Full review led to exclusions 
 8 duplicate studies 
 7 masses over 5 cm 
 4 no nephrectomy group 
 3 ex vivo 
 1 endoscopic US 
Original Search: 572 articles 
369 MEDLINE 
203 EMBASE 
 
Identified for Full Review: 37 articles 
20 MEDLINE 
17 EMBASE 
Included in Final Analysis: 11 articles 
8 MEDLINE 
3 EMBASE 
 
Hand searched 
reference lists 
Title review led to exclusions: 
Non-renal malignancies 
Editorials/letters  
Studies not discussing 
biopsy  
Individual case reports 
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Results 
Study Selection 
The PUBMED search resulted in 369 articles, which we narrowed down to 123 based on the 
titles of the articles. We subsequently reviewed 123 abstracts and from these, chose 9 papers to 
include in the study. The EMBASE search yielded 203 articles, which we narrowed down to 39 
articles based on titles. We subsequently reviewed 39 abstracts, and chose 3 papers to include in 
the study. There was substantial overlap between the two databases despite efforts to prevent 
duplication. Because we searched EMBASE after PUBMED many of the papers from the 
EMBASE search were already included because they arose in the PUBMED database.  
FNA versus core 
Eight of the studies used needle core biopsy rather than fine needle aspiration, however three 
studies did use both methods. In the study by Veltri et al., interventional radiologists only used 
FNA technique when a pathologist was present in the room.  
CT/US guided 
While many studies included both computed tomography and ultrasound-guided biopsy, very 
few presented details on the performance of one compared with the other. Nine of the studies 
reported use of both CT and ultrasound, while one study reported ultrasound-guided only, and 
another reported CT only. Only Volpe et al. reported an analysis of one method versus the other 
and found that there was no statistical significance between the accuracy of ultrasound-guided 
biopsy versus CT-guided biopsy. There was also no statistically significant improvement when 
using both methods
30
.   
Adequate tissue for diagnosis 
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One of the central arguments against biopsy has been that it often yields inadequate tissue for 
diagnosis. While we did not search for this specifically, all of the studies included in the analysis 
provided this information. The values ranged from as low as 68.5% adequate biopsy in the 
Vasudevan et al. study to 100% adequate biopsy in the Lebret et al. study. All of the studies used 
18 gauge needles to perform core biopsy, with the exception of the Somani et al. study using 16 
and 18 gauge needles and the Vasudevan study using 16 gauge needles only. No stratification 
was provided based on needle size in the Somani study, but it is interesting that the lowest rate of 
successful biopsies was reported in the study using exclusively the largest gauge needle
48
. In the 
studies using FNA technique, one did not report needle size
49
, one used 22 gauge needles
30
 and 
another reported 21-22 gauge use
50
.  
Many studies described normal renal parenchyma (i.e. not the mass), necrotic or 
hemorrhagic areas, inflammation, fibrosis, or specimens in which the tissue origin could not be 
determined. Depending on the study, the numbers are derived from either the first biopsy taken, 
with subsequent re-biopsy success rates reported, or in many studies, patients went on to repeat 
biopsy if the first sample was inadequate and these numbers are included in the total percentage 
of adequate biopsies. The Schmidbauer et al. study reported two different rates of adequate 
biopsy, 89% FNA, and 97% for core biopsy. For FNA, failed biopsies reported no cells in one 
sample and blood cells only in the remaining samples, while core biopsy showed normal renal 
parenchyma. This study eventually stopped using FNA after the first 44 patients.  
Sensitivity for Benign versus Malignant 
Despite our initial interest in sensitivity and specificity, only two studies reported these values 
and the other nine reported “accuracy” values. In these studies, accuracy for distinguishing 
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benign versus malignant pathology ranges from 92% to 100% in those with adequate biopsy. The 
Veltri et al. study reported accuracy for FNA alone as 88.4%, core biopsy alone as 94.8%, and in 
those undergoing both FNA and core biopsy, they reported an accuracy of 94.8%. Maturen et al. 
reported a sensitivity of 85/87 (97.7%) and a specificity of 100% for diagnosing benign versus 
malignant pathology. The two incorrect diagnoses in the sensitivity calculation were not 
“benign” but rather “nondiagnostic” biopsies that turned out to be malignant on nephrectomy. In 
all of the studies, substantially fewer patients underwent nephrectomy than had a diagnostic 
biopsy. There were very few nephrectomy specimens for those with a benign biopsy. In all but 
one paper, accuracy was only reported for the subset of patients with a diagnostic biopsy that 
went on to nephrectomy, because the nephrectomy specimen could serve as a gold standard. 
However, Maturen et al. created criteria under which they considered an observed patient with a 
benign biopsy correctly diagnosed after two years of no mass growth or symptoms.  
RCC subtype 
Although not as many studies reported accuracy for RCC subtype as did for benign versus 
malignant, for those studies that did, the numbers ranged from 82% to 100% accurate. 
Schmidbauer et al. reported values stratified by FNA versus core biopsy and showed that 
accuracy for subtype was 89% in FNA while it was 97% in core biopsy
49
. Two studies, one by 
Jaff et al. and the other by Volpe et al. both reported 100% in accuracy in RCC subtyping with 
sample sizes of 20 and 27, respectively. Fuhrman grading, only reported in four studies, ranged 
from 28% to 76% accurate depending on whether the study used FNA or core biopsy. Lebret et 
al. found 76% accuracy when reporting Fuhrman grade as high versus low, which may have 
significance with regards to further treatment
51
.  
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Adverse Events 
Though definitions of adverse events were not standardized, the majority of studies 
dichotomized adverse events into significant versus insignificant, or major versus minor groups. 
In most cases, major adverse events required intervention, an emergency room visit, or hospital 
admission. Minor events were those that could be monitored without any action. Studies differed 
in their post-procedure protocols, with some centers performing ultrasound on all patients who 
underwent biopsy, while others only took action if complications arose. No studies reported 
needle track seeding, a major source of concern in early studies. The Wang et al. study reported 
the highest rate of complications requiring intervention, at 7.3%. Six studies reported either no 
complications or only minor events requiring no intervention. The Vasudevan study reported one 
complication in which a patient needed two units of red blood cells, while Maturen et al. reported 
one patient who needed four units. The total number of biopsies in all the studies considered is 
1242 and the total number of serious complications (emergency room visit, admission, or 
medical intervention) reported was 14, resulting in a rate of 1.1%.  
Management of Benign Biopsy 
The management of those patients with a benign biopsy varied across studies. Six of the studies 
reported no scenarios in which patients with a benign biopsy underwent nephrectomy and even 
in the five studies that did, the numbers were all in the single digits. Average follow-up of 
nonsurgical patients ranged from 9.7 months in the Maturen et al. study to 37 months in the 
Veltri et al. study. The most comprehensive definition of benign biopsy came from the Maturen 
et al. study, in which the authors defined “definitely benign” as those with no growth at two 
years and “probably benign” as those with no growth at six months to two years. The majority of 
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studies reported surveillance regimens using CT or MRI every six months, with some spacing 
out imaging to once a year after a certain amount of time with no growth. The Shannon et al. 
study reported growth of monitored lesions, but reported no symptoms or subsequent surgery for 
the masses.  
Change in Management 
Because eight of the eleven studies were retrospective, the authors reported results as if they 
would have changed management. These changes referred to patients avoiding surgery based on 
biopsy diagnosis of benign lesions, diagnosis of low grade lesions, or diagnosis of metastases 
that required treatment of the initial cancer rather than nephrectomy. In other cases, the biopsy 
results affected the type of surgery (i.e. nephron sparing surgery versus radical nephrectomy) or 
led physicians to use radio frequency ablation techniques rather than extirpative surgery. Even in 
cases where surveillance was planned initially, a benign biopsy led to less strict surveillance 
protocols. Eight of the studies reported the percentage of patients with a change in a 
management, with numbers ranging from 15% to 69% of patients affected.   
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Study Initial 
Assembly of 
Comparable 
Groups 
Differential or 
high loss to follow-
up 
Measurement Clear 
definition of 
intervention
s 
Important 
outcomes 
considered 
Adjustment 
for potential 
confounders 
Grade 
Wang 
52
 no 3% benign biopsies 
lost to follow-up. 
0% of malignant 
Details of 
IHC-unknown. 
Biopsy 
pathology 
compared to 
nephrectomy 
pathology 
yes yes no poor 
Volpe 
30
 no No reported loss to 
follow-up 
Details of 
IHC-yes. 
Biopsy 
pathology 
compared to 
nephrectomy 
pathology 
yes yes no poor 
Shannon
53
 no 7/28 patients with 
no diagnosis lost to 
follow-up. 0 
patients with 
diagnostic biopsy 
lost to follow-up  
Details of 
IHC-unknown. 
Biopsy 
pathology 
compared to 
nephrectomy 
pathology 
yes yes no poor 
Schmidbauer
49
 no No report of loss to 
follow-up 
Details of 
IHC- 
unknown. 
Biopsy 
pathology 
compared to 
nephrectomy 
pathology 
yes yes no poor 
Lebret 
51
 no No report of loss to 
follow-up 
Details of 
IHC-yes. 
Biopsy 
pathology 
compared to 
nephrectomy 
pathology 
yes yes no poor 
Reichelt 
54
 no No report of loss to 
follow-up 
Details of 
IHC-yes. 
Biopsy 
pathology 
compared to 
nephrectomy 
pathology 
yes yes no poor 
Maturen 
20
 no No report of loss to 
follow-up 
Details of 
IHC-unknown. 
Biopsy 
pathology 
compared to 
nephrectomy 
pathology 
yes yes no poor 
Somani 
47
 no 1/27 in biopsy Details of yes yes no poor 
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nephrectomy group. 
14/149 in 
nonbiopsy 
nephrectomy group 
IHC-yes. 
Biopsy 
pathology 
compared to 
nephrectomy 
pathology 
Vasudevan 
48
 no No report of loss to 
follow-up 
Details of 
IHC-unknown. 
Biopsy 
pathology 
compared to 
nephrectomy 
pathology 
yes yes no poor 
Veltri 
50
 no 12/150 biopsies lost 
to follow-up, no 
further details 
provided 
Details of 
IHC-unknown. 
Biopsy 
pathology 
compared to 
nephrectomy 
pathology 
yes yes no poor 
Jaff 
55
 no No report of loss to 
follow-up 
Details of 
IHC-unknown. 
Biopsy 
pathology 
compared to 
nephrectomy 
pathology 
yes yes no poor 
Table 2. Quality criteria adapted from USPSTF cohort study quality criteria. 
*important outcomes: findings on biopsy, findings on nephrectomy (if available), adverse events, 
tumor seeding, death 
**IHC- immunohistochemistry  
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Study # biopsies Mean tumor size Mean Age 
(years) 
% Male 
Wang 110 2.7 cm 60.4  68% 
Volpe 100 2.4 cm 60 (median) unknown 
Shannon 235 2.9 cm (median) 64  unknown 
Schmidbauer 122 4 cm 63 80% 
Lebret 119 3.3 cm 66.5 60% 
Reichelt 30 2.9 cm 63 60% 
Maturen 152 4.1 cm 60 46% 
Somani 70 unknown 63.8 61% 
Vasudevan 100 unkown 62 unknown 
Veltri 150 3.4 cm 64.5 63% 
Jaff 54 3.3 cm 72 (median) 60% 
Table 3. Study Characteristics 
 
Study FNA vs core Gauge Needle CT/US guided % adequate 
tissue for dx 
Wang core 18 gauge 66 CT, 44 US 100/110 (90.9%) 
Volpe both 18 core  
22 FNA 
45 US, 11 CT, 
44 both 
84/100 (84%) 
Shannon core 18 gauge both 184/235 (78.3%) 
Schmidbauer both 18 core 
FNA not specified   
CT 89% in FNA 
97% in core 
Lebret core 18 gauge both 79% 
Reichelt core 18 gauge US 25/30 (83%) 
Maturen core 18 gauge 76 US, 76 CT 146/152 (96%) 
Somani core 16-18 gauge both 61/70 (87.1%) 
Vasudevan core 16 gauge both 63/92 (68.5%) 
Veltri both Core not specified 
21-22g FNA 
145 US, 5 CT Not reported 
Jaff core 18 gauge 6 US, 48 CT 46/54 (85.1%) 
Table 4. Study Characteristics Continued 
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Study Accuracy 
Benign vs 
Malig 
Accuracy 
RCC 
subtype 
Accuracy for 
Fuhrman 
grade 
Adverse 
Events 
Change in 
Management 
Wang 34/34 (100%) 28/29 
(96.6%) 
- 8/110= 7% Not reported 
Volpe 20/20 (100%) 20/20 
(100%) 
8/12 (66.7%) none 43/100 (43%) 
Shannon 108/108 (100%) 106/108 
(98%) 
- 2/108 (0.9%) 62/235 (26%) 
Schmidbauer 95.2% (core 
sens) 
100% (core 
spec) 
90.6% (FNA 
sens) 
100% (FNA 
spec) 
91% core 
86% FNA 
 
28% FNA 
76% core 
None 
requiring 
intervention 
19/122 
(15.6%) 
Lebret Not presented 86% 46% 
76% if high 
vs low 
none 31/102 (30%) 
Reichelt 17/17 (100%) - - 1 renal 
hematoma 
Not reported 
Maturen 97.7% 
(sensitivity) 
100% 
(specificity) 
- - 2 post-
procedure 
hematomas, 
1 needing 4 
units pRBC 
90/152 
(60.5%) 
Somani 32/32 (100%) - - 1 requiring 
admission 
17/70 (24%) 
Vasudevan 38/38 (100%) - - 1 pt needed 2 
units blood 
Not reported 
Veltri 119/129 (92.2%) - - 8/150 (5.3%) 89/150 
(68.9%) 
Jaff 100% 100% 75% none 32/46 (69.6%) 
Table 5. Review findings for benign vs. malignant, RCC subtype, Fuhrman grade, adverse events 
and change in management. 
*no cases of needle track seeding were reported 
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Study Study Design Inclusion 
Criteria 
Blinding of 
pathologists? 
Details of 
immunohistochemistry 
Wang retrospective case 
series 
SRM ≤ 4 cm. 
Adults over 18, 
excluded cystic 
masses 
unknown unknown 
Volpe retrospective case 
series 
Incidental, isolated 
SRM ≤4 cm. 
unknown yes 
Shannon retrospective case 
series 
Incidental, 
asymptomatic mass 
under 5 cm 
unknown unknown 
Schmidbauer prospective case 
series 
Solid renal masses, 
cystic excluded   
unknown unknown 
Lebret retrospective case 
series 
SRM ≤ 4 cm or 
those missing 
radiologic criteria 
unknown yes 
Reichelt prospective case 
series 
Noncystic, 
homogenous masse 
found on US 
unknown yes 
Maturen retrospective case 
series 
- unknown unknown 
Somani prospective case 
series 
Biopsied those in 
which "it was not 
possible to 
characterize renal 
masses as either 
malignant or benign 
on imaging 
characteristics 
alone" 
 
unknown yes 
Vasudevan retrospective case 
series 
Asymptomatic, 
incidental masses 
under 5 cm 
unknown unknown 
Veltri retrospective case 
series 
Radiology did not 
provided sufficient 
diagnosis 
unknown unknown 
Jaff retrospective case 
series 
Solitary kidney, 
RFA candidate, 
suspect oncoytoma, 
lymphoma or mets, 
high risk for 
surgery 
unknown unknown 
Table 6. Study Description 
*SRM= solitary renal masses  
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Discussion 
  The papers we reviewed claim promising results for the use of biopsy in lesions smaller 
than four centimeters. In these papers, biopsy was effective at distinguishing benign versus 
malignant masses; in the papers that reported it, biopsy could predict RCC subtype with accuracy 
in the 80-100% range. None of the papers reported needle track seeding, and major 
complications were rare. These findings coincide with other recent literature reviews on the 
subject that found improved sensitivity and specificity of renal mass biopsy and reported low 
rates of complications and no needle track seeding
19, 56
. Two recent studies found that Fuhrman 
grade was correctly interpreted in 70%
44
 and 83% 
7
 of cases, which also coincides with our 
findings.  
However, an important distinction must be made. As proposed in reviews by Lane et. al 
in 2008 and Samplaski et al. in 2010, the idea that biopsy failures should not be counted as false 
negatives is a departure from past literature
46, 57-62
. Changing these denominators can give 
substantially higher values for sensitivity depending on the rate of biopsy failure, which may not 
be an entirely accurate representation of the data. By not counting these patients, some argue that 
the numbers ignore the non-trivial process of going through biopsy after which there is no 
additional information. While this is true, the rate of complications in our study is very low. 
Additionally, we argue that clinicians and pathologists know that a failed biopsy does not 
indicate benign status and would not make patient care decisions under this assumption. Thus, an 
important category for studies on this topic to include is “percentage/proportion of adequate 
biopsy.”  Using this model, sensitivity and specificity calculations can be supplemented by 
information about the frequency of biopsy failure. We do worry however, that the increase in 
sensitivity reported in our review and other recent reviews compared to previous studies may be 
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due in part to this method of reporting; a true comparison to previous studies is difficult because 
of this change in the denominator. 
Even if renal mass biopsy is safer and more accurate than previously thought, questions 
have arisen about the costs incurred by this approach. A cost-effectiveness analysis by 
Pandharipande, et al. showed that the risks that have kept physicians from using renal biopsy are 
“at least equaled by those risks incurred by performing empiric surgery in all patients.” The 
Markov model developed in the paper used a base-case of a 65 year old man with an incidentally 
detected tumor under four centimeters who could undergo empiric surgery or tumor surveillance. 
The base-case sensitivity and specificity were 0.9 and 1, respectively, but sensitivity analyses for 
both values ranged from 0.5 to 1. By using a quasi-societal model, the authors did not factor in 
time costs to the patient. Using the base-case model, the biopsy strategy yielded a four day 
longer life expectancy with a $3466 lower lifetime cost than empiric nephron sparing surgery. 
The biopsy strategy also dominated across the majority of sensitivity ranges during a one-way 
sensitivity analysis. Even when the mortality of nephron sparing surgery was assumed to be 0%, 
the empiric surgery model did not dominate the biopsy model. However, when biopsy sensitivity 
fell to less than 0.78, the surgical model dominated the biopsy model. Based on findings from the 
studies that we reviewed, the biopsy model should dominate in the current environment. 
Limitations of the study should not nullify its findings, but they are worth considering. For 
example, because there is limited data on surveillance studies, the authors concede that it was 
difficult to model biopsy negative tumor outcomes. The authors also note that there are no 
accepted guidelines for surveillance, which creates difficulty in making assumptions for the 
model
63
.  
Limitations of Current Research 
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Despite increased interest in the area of renal mass biopsy, the current research still has many 
limitations. Based on USPSTF quality criteria, all of the papers in our study earned a poor 
quality rating. The majority of the studies are retrospective case series from major academic 
medical centers, in which patient outcomes are reported from medical records that are often 
lacking demographic information and long-term follow-up. All of the studies lacked 
randomization and control groups, and no study adjusted for baseline status of patients or other 
possible confounding variables.  Additionally, many studies do not elaborate on inclusion criteria 
for biopsy. For the purposes of our research question, it is important that patients undergo biopsy 
for an asymptomatic incidental renal mass, because this is the clinical scenario that perplexes 
urologists most.  
The biggest limitation of all of the studies is the fact that not all patients go on to 
nephrectomy. In six of the papers we reviewed, zero percent of patients with benign biopsy 
results went on to nephrectomy, and in others, the numbers were in the single digits. Without a 
true gold standard to compare benign biopsy results to, the sensitivity and specificity calculations 
based on these findings are not dependable. Only one study used a time cut-off of two years, 
after which a benign biopsy result would be considered correct if the mass had not increased in 
size or become symptomatic. Differing follow-up protocols at different institutions make this 
determination even more complex. Importantly, some studies have shown malignant masses for 
which no growth was observed during surveillance
64
.  Under this scenario, sensitivity and 
accuracy values would be inflated because benign biopsies are being considered correct due to 
the mass’s indolent growth, when in fact they are malignant and the biopsy findings are wrong. 
In addition to follow-up not being standardized, many authors admit that studies are potentially 
not long enough to detect whether benign lesions are truly benign; a similar stance has been 
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raised regarding tumor seeding, noting that studies may not have followed patients long enough 
to detect seeding if it occured later on.  
The behavior of supposedly benign masses under surveillance is an important aspect of 
the conclusions of the studies. Because of a lack of nephrectomy follow-up in benign biopsy, 
authors were forced to use growth-free or symptom-free surveillance periods as the gold standard 
for an accurate benign biopsy. This is problematic if, as some studies have suggested, growth-
free or symptom-free masses can still go on to be malignant. In a 2004 study by Wehle et. al, out 
of 29 patients enrolled in a surveillance program, the authors reported three cases that went on to 
nephrectomy because of patient wishes (i.e. not symptoms or substantial growth) and were found 
to be RCC. For two of these, they reported no growth in 12 months and 38 months of follow-up, 
respectively. For the third case, they reported a 0.2 cm/year growth rate during 43 months of 
follow-up
35
. Though this study did have a relatively small sample size, and the majority of 
patients continued surveillance with no deaths or reports of metastases, the study casts doubt on 
the use of growth-free surveillance as a true marker of benignity. However, growth-free 
malignant masses may not be clinically significant if they remain growth-free or grow at a very 
slow pace. For patients with a limited life expectancy, a mass growing at 0.2 cm/year could be 
inconsequential even if it is histologically malignant. A longer term study could provide 
information about the growth of such masses; unfortunately, because of the apprehension of 
urologists to observe renal masses, there are few surveillance studies in the literature. 
All of the case series in our review are published from major academic medical centers 
throughout the United States and Europe. This adversely affects the generalizability of the study 
as patients referred to academic medical centers are not an accurate representation of the general 
population. Similarly, surgeons performing at major academic medical centers often have had 
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more training and are exposed to higher case volumes than those practicing in community 
settings. For these reasons, reported outcomes and complications may not accurately portray 
results in other settings. 
Future Studies 
Here, we propose the design of future studies that would address many of the logistic and 
epidemiologic shortfalls of the current research. All of the studies in our review were case series 
reported from major academic medical centers, where patients are more rigorously selected and 
can introduce unpredictable bias into conclusions.  To strengthen generalizability, patients in 
future studies should be enrolled from population-based registries such as the VA Hospital 
system or Kaiser because these are more representative of populations across the country. We 
propose that patients who pose a therapeutic dilemma be pre-specified in some way. For 
example, those with tumors under 4 cm, age over 65 years old, or those with a pre-defined set of 
comorbidities that make surgery a less than ideal option. From this point, these patients could be 
randomized to renal mass biopsy or watchful waiting. In the biopsy group, further treatment 
would be dictated by biopsy results; type of surgery, biopsy technique, and 
immunohistochemistry should be standardized to ensure comparability. A standardized follow-
up protocol should also be specified; for example, in the first two years, patients would receive 
CT scans every six months, and if no change is observed, they would subsequently be scanned 
once a year. Mortality, progression to cancer, and rate of complications could be compared at 
one, five, and ten year periods. This would be a distinct improvement over the current literature 
because of the addition of a prospective design, randomization, and a comparison group. From 
these same population-based registries, studies can report mortality, oncologic outcomes, and 
complication rate for those patients who do undergo nephrectomy. These findings would be more 
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generalizable than case series reporting surgical outcomes of highly selected patients at academic 
medical centers.  
Future Direction 
Renal epithelial cancers are a diverse group with differing natural histories and prognoses 
due to their own cytogenetic and molecular aberrations
65
. A series of studies have reported 
improvements in biopsy results with the addition of cytogenetic studies. In a paper by Barocas
65
 
et al., the authors combined histopathology with a molecular diagnostic algorithm presented in a 
previous study
66
 to improve diagnostic accuracy of core biopsy. This algorithm is based on high 
CA9 expression in clear cell carcinoma, AMACR in papillary RCC, and CLCNKB in 
chromophobe RCC and oncocytoma
66
. The study reported the diagnostic accuracy of biopsy 
improved from 83.3% to 95% (57 of 60 biopsies) when histology was combined with the 
molecular diagnostic algorithm compared to histology alone. The combination increased 
sensitivity from 87.1% to 100% and improved the negative predictive value from 87.5% to 
100%
65
. However, this study has limited generalizability because of the ex-vivo sampling of 
kidney masses. Direct visualization and palpation of masses in the study make extrapolation to a 
true biopsy scenario difficult. Additionally, the authors report using a 14 gauge needle for biopsy 
which is substantially larger than the more routinely used 18 gauge needle found in the studies 
we reviewed. The authors note that there is currently no molecular marker than can distinguish 
between chromophobe renal cell carcinoma from oncocytoma, which is an often a source of 
incorrect diagnoses.  
 A similar study was done in 2006 that combined fluorescent in-situ hybridization (FISH) 
with histology to improve biopsy accuracy. The authors reported the use of six probes based on 
the most common mutations in renal cell carcinoma: loss of von Hippel-Lindau (VHL) locus of 
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chromosome 3p in clear cell RCC, trisomy 7 and 17 in papillary RCC, and losses of parts of 
chromosomes 10, 13, 17 or 21 in chromophobe RCC
67
. The paper showed that adding FISH led 
to the correct identification of four additional tumors out of 36 total masses, improving the 
accuracy of biopsy from 75% to 86%. The study shares weaknesses with the aforementioned 
study in its ex-vivo design and use of 14 gauge needles. Additionally, FISH is accurate for 
detecting losses and translocations, but can miss mutations, which can be relevant in clear cell 
carcinoma
67
. If costs can kept under control, molecular studies could be the future of renal mass 
management as they will increase diagnostic capabilities and tailor treatment to specific 
individuals.  
 Despite increased interest in the topic of RCC, the available literature is composed of low 
quality studies that lack prospective design, randomization, and generalizability. Keeping this in 
mind, our review of the literature showed that sensitivity and specificity of renal mass biopsy for 
differentiating benign and malignant pathology is improving compared to previously published 
studies and textbooks. We worry, however, that the design of these studies may inflate sensitivity 
values by leaving failed or indeterminate biopsies out of the denominator. Our study also found a 
low level of complications and zero reports of needle track seeding, although questions remain 
about the adequacy of follow-up to assess these findings. The findings of this review show that 
there is much work left to be done in the area of RCC research. A large, population-based, 
randomized trial is needed to assess the effect of biopsy on mortality and cancer progression 
which can then be applied to the general population.   
  
 34 
 
REFERENCES  
 
1. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader 
N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, 
Stinchcomb DG, Edwards BK (eds). SEER cancer statistics review, 1975-2007. 
http://seer.cancer.gov/csr/1975_2007/.  
2. Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. 
Urology. 1998;51(2):203-205.  
3. Chow WH, Devesa SS, Warren JL, Fraumeni Jr JF. Rising incidence of renal cell cancer in the 
united states. JAMA. 1999;281(17):1628.  
4. Gill IS, Matin SF, Desai MM, et al. Comparative analysis of laparoscopic versus open partial 
nephrectomy for renal tumors in 200 patients. J Urol. 2003;170(1):64-68.  
5. Gill IS, Kavoussi LR, Lane BR, et al. Comparison of 1,800 laparoscopic and open partial 
nephrectomies for single renal tumors. J Urol. 2007;178(1):41-46.  
6. Lechevallier E, André M, Barriol D, et al. Fine-needle percutaneous biopsy of renal masses 
with helical CT Guidance1. Radiology. 2000;216(2):506.  
7. Neuzillet Y, Lechevallier E, Andre M, Daniel L, Coulange C. Accuracy and clinical role of 
fine needle percutaneous biopsy with computerized tomography guidance of small (less than 4.0 
cm) renal masses. J Urol. 2004;171(5):1802-1805.  
8. Zhou M, Roma A, Magi-Galluzzi C. The usefulness of immunohistochemical markers in the 
differential diagnosis of renal neoplasms. Clin Lab Med. 2005;25(2):247-257.  
9. Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. J Urol. 
2006;176(6):2353-2358.  
10. Bjørge T, Tretli S, Engeland A. Relation of height and body mass index to renal cell 
carcinoma in two million norwegian men and women. Am J Epidemiol. 2004;160(12):1168.  
11. Ficarra V, Schips L, Guillè F, et al. Multiinstitutional european validation of the 2002 TNM 
staging system in conventional and papillary localized renal cell carcinoma. Cancer. 
2005;104(5):968-974.  
12. Belldegrun A, MD, Blute MM, Chow GKM, et al. Guidelines for the management of a 
clinical stage 1 renal mass. American Urologic Association. 2009.  
13. Miller DC, Ruterbusch J, Colt JS, et al. Contemporary clinical epidemiology of renal cell 
carcinoma: Insight from a population based case-control study. J Urol. 2010.  
14. Cooperberg MR, Mallin K, Ritchey J, Villalta JD, Carroll PR, Kane CJ. Decreasing size at 
diagnosis of stage 1 renal cell carcinoma: Analysis from the national cancer data base, 1993 to 
2004. J Urol. 2008;179(6):2131-2135.  
15. Hollenbeck BK, Taub DA, Miller DC, Dunn RL, Wei JT. National utilization trends of 
partial nephrectomy for renal cell carcinoma: A case of underutilization? Urology. 
2006;67(2):254-259.  
16. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal 
masses: A need to reassess treatment effect. J Natl Cancer Inst. 2006;98(18):1331.  
17. Silverman S, Lee B, Seltzer S, Bloom D, Corless C, Adams D. Small (< or= 3 cm) renal 
masses: Correlation of spiral CT features and pathologic findings. Am J Roentgenol. 
1994;163(3):597.  
18. Li G, Cuilleron M, GENTIL‐PERRET A, Tostain J. Characteristics of image‐detected solid 
renal masses: Implication for optimal treatment. International Journal of Urology. 
2004;11(2):63-67.  
 35 
 
19. Lane BR, Samplaski MK, Herts BR, Zhou M, Novick AC, Campbell SC. Renal mass biopsy-
-A renaissance? J Urol. 2008;179(1):20-27.  
20. Maturen KE, Nghiem HV, Caoili EM, Higgins EG, Wolf Jr JS, Wood Jr DP. Renal mass 
core biopsy: Accuracy and impact on clinical management. Am J Roentgenol. 2007;188(2):563.  
21. Silverman SG, Gan YU, Mortele KJ, Tuncali K, Cibas ES. Renal masses in the adult patient: 
The role of percutaneous Biopsy1. Radiology. 2006;240(1):6.  
22. Bosniak MA, Megibow AJ, Hulnick DH, Horii S, Raghavendra BN. CT diagnosis of renal 
angiomyolipoma: The importance of detecting small amounts of fat. Am J Roentgenol. 
1988;151(3):497.  
23. Bosniak MA. Angiomyolipoma (hamartoma) of the kidney: A preoperative diagnosis is 
possible in virtually every case. Urol Radiol. 1981;3(3):135-142.  
24. Zagoria RJ. Imaging of small renal masses: A medical success story. Am J Roentgenol. 
2000;175(4):945.  
25. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335(12):865-
875.  
26. Novick AC, Derweesh I. Open partial nephrectomy for renal tumours: Current status. BJU 
Int. 2005;95 Suppl 2:35-40.  
27. Steinbach F, Stockle M, Hohenfellner R. Clinical experience with nephron-sparing surgery in 
the presence of a normal contralateral kidney. Semin Urol Oncol. 1995;13(4):288-291.  
28. Petritsch PH, Rauchenwald M, Zechner O, et al. Results after organ-preserving surgery for 
renal cell carcinoma. an austrian multicenter study. Eur Urol. 1990;18(2):84-87.  
29. Van Poppel H, Da Pozzo L, Albrecht W, et al. A prospective, randomised EORTC intergroup 
phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical 
nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2010.  
30. Volpe A, Mattar K, Finelli A, et al. Contemporary results of percutaneous biopsy of 100 
small renal masses: A single center experience. J Urol. 2008;180(6):2333-2337.  
31. Davis CJ,Jr. Pathology of renal neoplasms. Semin Roentgenol. 1987;22(4):233-240.  
32. Lane BR, Gill IS. 5-year outcomes of laparoscopic partial nephrectomy. J Urol. 
2007;177(1):70-74.  
33. Venkatesh R, Weld K, Ames CD, et al. Laparoscopic partial nephrectomy for renal masses: 
Effect of tumor location. Urology. 2006;67(6):1169-1174.  
34. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. Solid renal tumors: An 
analysis of pathological features related to tumor size. J Urol. 2003;170(6):2217-2220.  
35. Wehle MJ, Thiel DD, Petrou SP, Young PR, Frank I, Karsteadt N. Conservative management 
of incidental contrast-enhancing renal masses as safe alternative to invasive therapy. Urology. 
2004;64(1):49-52.  
36. Campbell SC, Novick AC, Herts B, et al. Prospective evaluation of fine needle aspiration of 
small, solid renal masses: Accuracy and morbidity. Urology. 1997;50(1):25-29.  
37. Smith EH. Complications of percutaneous abdominal fine-needle biopsy. review. Radiology. 
1991;178(1):253.  
38. WOOD BJ, KHAN MA, McGOVERN F, HARISINGHANI M, HAHN PF, MUELLER PR. 
Imaging guided biopsy of renal masses: Indications, accuracy and impact on clinical 
management. J Urol. 1999;161(5):1470-1474.  
39. Shenoy P, Lakhkar B, Ghosh M, Patil U. Cutaneous seeding of renal carcinoma by chiba 
needle aspiration biopsy. Acta Radiol. 1991;32(1):50-52.  
 36 
 
40. Eshed I, Elias S, Sidi A. Diagnostic value of CT-guided biopsy of indeterminate renal 
masses. Clin Radiol. 2004;59(3):262-267.  
41. Wehle MJ, Grabstald H. Contraindications to needle aspiration of a solid renal mass: Tumor 
dissemination by renal needle aspiration. J Urol. 1986;136(2):446-448.  
42. Richter F, Kasabian N, IrwinJr R, Watson R, Lang E. Accuracy of diagnosis by guided 
biopsy of renal mass lesions classified indeterminate by imaging studies. Urology. 
2000;55(3):348-352.  
43. Herts BR, Remer E. The role of percutaneous biopsy in the evaluation of renal and adrenal 
mass. AUA Update Series. 2000;19:282-287.  
44. Wunderlich H, Hindermann W, Mustafa AMA, Reichelt O, Junker K, Schubert J. The 
accuracy of 250 fine needle biopsies of renal tumors. J Urol. 2005;174(1):44-46.  
45. Truong LD, Todd TD, Dhurandhar B, Ramzy I. Fine-needle aspiration of renal masses in 
adults: Analysis of results and diagnostic. Diagn Cytopathol. 1999;20(6):339.  
46. Murphy WM, Zambroni BR, Emerson LD, Moinuddin S, Lee LH. Aspiration biopsy of the 
kidney. simultaneous collection of cytologic and histologic specimens. Cancer. 1985;56(1):200-
205.  
47. Somani BK, Nabi G, Thorpe P, N'Dow J, Swami S, McClinton S. Image-guided biopsy-
diagnosed renal cell carcinoma: Critical appraisal of technique and long-term follow-up. Eur 
Urol. 2007;51(5):1289-1297.  
48. Vasudevan A, Davies RJ, Shannon BA, Cohen RJ. Incidental renal tumours: The frequency 
of benign lesions and the role of preoperative core biopsy. BJU Int. 2006;97(5):946-949.  
49. Schmidbauer J, Remzi M, Memarsadeghi M, et al. Diagnostic accuracy of computed 
tomography-guided percutaneous biopsy of renal masses. Eur Urol. 2008;53(5):1003-1012.  
50. Veltri A, Garetto I, Tosetti I, et al. Diagnostic accuracy and clinical impact of imaging-
guided needle biopsy of renal masses. retrospective analysis on 150 cases. Eur Radiol. 2010:1-9.  
51. Lebret T, Poulain JE, Molinie V, et al. Percutaneous core biopsy for renal masses: 
Indications, accuracy and results. J Urol. 2007;178(4):1184-1188.  
52. Wang R, Wolf Jr JS, Wood Jr DP, Higgins EJ, Hafez KS. Accuracy of percutaneous core 
biopsy in management of small renal masses. Urology. 2009;73(3):586-590.  
53. Shannon BA, Cohen RJ, de Bruto H, Davies RJ. The value of preoperative needle core 
biopsy for diagnosing benign lesions among small, incidentally detected renal masses. J Urol. 
2008;180(4):1257-1261.  
54. Reichelt O, Gajda M, Chyhrai A, Wunderlich H, Junker K, Schubert J. Ultrasound-guided 
biopsy of homogenous solid renal masses. Eur Urol. 2007;52(5):1421-1427.  
55. Jaff A, Molinié V, Mellot F, Guth A, Lebret T, Scherrer A. Evaluation of imaging-guided 
fine-needle percutaneous biopsy of renal masses. Eur Radiol. 2005;15(8):1721-1726.  
56. Samplaski MK, Zhou M, Lane BR, Herts B, Campbell SC. Renal mass sampling: An 
enlightened perspective. International Journal of Urology.  
57. Holm HH, Pedersen JF, Kristensen JK, Rasmussen SN, Hancke S, Jensen F. Ultrasonically 
guided percutaneous puncture. Radiol Clin North Am. 1975;13(3):493-503.  
58. Nosher JL, Amorosa JK, Leiman S, Plafker J. Fine needle aspiration of the kidney and 
adrenal gland. J Urol. 1982;128(5):895-899.  
59. Juul N, Torp-Pedersen S, Grønvall S, Holm H, Koch F, Larsen S. Ultrasonically guided fine 
needle aspiration biopsy of renal masses. J Urol. 1985;133(4):579-581.  
60. Dekmezian R, Charnsangavej C, Rava P, Katz R. Fine needle aspiration of kidney tumors in 
105 patients: A cytologic and histologic correlation. Acta Cytol. 1985;29:931.  
 37 
 
61. Leiman G. Audit of fine needle aspiration cytology of 120 renal lesions. Cytopathology. 
1990;1(2):65-72.  
62. Niceforo J, Coughlin B. Diagnosis of renal cell carcinoma: Value of fine-needle aspiration 
cytology in patients with metastases or contraindications to nephrectomy. Am J Roentgenol. 
1993;161(6):1303.  
63. Pandharipande PV, Gervais DA, Hartman RI, et al. Renal mass biopsy to guide treatment 
decisions for small incidental renal tumors: A cost-effectiveness Analysis1. Radiology. 
2010;256(3):836.  
64. Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DYT, Uzzo RG. The natural 
history of observed enhancing renal masses: Meta-analysis and review of the world literature. J 
Urol. 2006;175(2):425-431.  
65. Barocas D, Rohan S, Kao J, et al. Diagnosis of renal tumors on needle biopsy specimens by 
histological and molecular analysis. J Urol. 2006;176(5):1957-1962.  
66. Chen YT, Tu JJ, Kao J, Zhou XK, Mazumdar M. Messenger RNA expression ratios among 
four genes predict subtypes of renal cell carcinoma and distinguish oncocytoma from carcinoma. 
Clinical cancer research. 2005;11(18):6558.  
67. Barocas DA, Mathew S, DelPizzo JJ, et al. Renal cell carcinoma sub‐typing by 
histopathology and fluorescence in situ hybridization on a needle‐biopsy specimen. BJU Int. 
2007;99(2):290-295.  
 
